GeoVax Labs
D

GOVX

2.13500
USD
2.02
(1,789.38%)
بعد الجلسة·2.16000USD+0.02500(+1.17%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
4,592
الربح لكل سهم
-3
العائد الربحي
-
P/E
-0
حجم السوق
19,415,415
نظرة عامة
أصول ذات صلة
DIABUSD
DIABUSDDIA / United States Dollar
0.23800
0.00035(0.15%)
GLD
GLD
D
SPDR Gold Trust SPDR Gold Shares
365.16
-4.19(-1.13%)
365.40+0.23(+0.06%)
IWM
IWM
D
iShares Russell 2000 ETF
283.09
2.51(0.89%)
283.18+0.09(+0.03%)
QQQ
QQQ
D
Invesco QQQ Trust Series 1
690.44
15.62(2.31%)
689.27-1.11(-0.16%)
SPY
SPY
D
State Street SPDR S&P 500 ETF Trust
759.79
9.89(1.32%)
759.40-0.41(-0.05%)
TLT
TLT
D
iShares 20 Year Treasury
80.940
0.040(0.05%)
80.931+0.011(+0.01%)
USO
USO
D
United States Oil Fund LP
141.470
0.020(0.01%)
141.530+0.060(+0.04%)
XLE
XLE
D
Select Sector Spdr Trust State Street Energy Select Sector SPDR E
63.360
1.160(1.86%)
63.371+0.001(0.00%)
XLF
XLF
D
Financial Select Sector SPDR Fund
58.610
0.340(0.58%)
58.660+0.030(+0.05%)
XLK
XLK
D
Select Sector Spdr Trust State Street Technology Select Sector SP
174.390
5.450(3.23%)
174.520+0.160(+0.09%)
المزيد

العنوان: Geovax Labs Inc

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

أسئلة شائعة حول سهم GeoVax Labs